Increased mortality and aggravation of heart failure in estrogen receptor-β knockout mice after myocardial infarction

Circulation

Volumn 111, Issue 12, 2005, Pages 1492-1498

  Pelzer, Theo ^a   Loza, Paula Anahi Arias ^a   Hu, Kai ^a   Bayer, Barbara ^a   Dienesch, Charlotte ^a   Calvillo, Laura ^b   Couse, John F ^c   Korach, Kenneth S ^c   Neyses, Ludwig ^d   Ertl, Georg ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Laboratory of Reproductive and Developmental Toxicology   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Heart failure; Hormones; Myocardial infarction; Receptors

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOCHEMICAL MARKER; ESTRADIOL; ESTROGEN RECEPTOR BETA; RECEPTOR SUBTYPE;

ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; FEMALE; FLUID RETENTION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; KNOCKOUT MOUSE; MORTALITY; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; SEX DIFFERENCE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BODY WEIGHT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ESTROGEN RECEPTOR BETA; FEMALE; GENOTYPE; HEART FAILURE, CONGESTIVE; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; PROTEINS; SURVIVAL RATE; VENTRICULAR REMODELING;

EID: 20144389505     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000159262.18512.46     Document Type: Article

References (38)

1. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
3. Green S, Walter P, Greene G, Krust A, Coffin C, Jensen E, Scrace G, Waterfield M, Chambon P. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem. 1986;24:77-83.
4. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93:5925-5930.
5. Couse JF, Korach KS. Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Ann Endocrinol (Paris). 1999;60:143-148.
6. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A. 1998;95:15677-15682.
7. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol Endocrinol. 2003; 17: 203-208.
8. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation. 1994;89:1943-1950.
9. Grohe C, Kahlert S, Lobbert K, Stimpel M, Karas RH, Vetter H, Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 1997;416:107-112.
10. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, O'Donnell TF Jr, Korach KS, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med. 1997;3:545-548.
11. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999;96:15133-15136.
12. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, Mendelsohn ME. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res. 2001;89:534-539.
13. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson JA, Mendelsohn ME. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science. 2002;295:505-508.
14. Modena MG, Muia N Jr, Aveta P, Molinari R, Rossi R. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension. 1999;34:1041-1046.
15. Pelzer T, de Jager T, Muck J, Stimpel M, Neyses L. Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition. J Hypertens. 2002;20:1001-1006.
16. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation. 2001;104:1419-1423.
17. Hugel S, Reincke M, Stromer H, Winning J, Horn M, Dienesch C, Mora P, Schmidt HH, Allolio B, Neubauer S. Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling. J Am Coll Cardiol. 1999;34:1427-1434.
18. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126-3132.
19. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, Galuppo P, Strotmann J, Ertl G, Bauersachs J. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol. 2004;141:9-14.
20. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
21. Haddy FJ. Heart failure: incidence and survival. N Engl J Med. 2003;348:660. Letter.
22. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
23. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
24. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
25. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohe C, van Bilsen M, Doevendans PA. 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation. 2004;109:269-276.
26. Schwartzbauer G, Robbins J. Matters of sex: sex matters. Circulation. 2001;104:1333-1335.
27. Emmen JM, Korach KS. Estrogen receptor knockout mice: phenotypes in the female reproductive tract. Gynecol Endocrinol. 2003;17:169-176.
28. Smith PJ, Ornatsky O, Stewart DJ, Picard P, Dawood F, Wen WH, Liu PP, Webb DJ, Monge JC. Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation. 2000;102:2983-2989.
29. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284:H1560-H1569.
30. van Eickels M, Patten RD, Aronovitz MJ, Alsheikh-Ali A, Gostyla K, Celestin F, Grohe C, Mendelsohn ME, Karas RH. 17-Beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol. 2003;41:2084-2092.
31. Patten RD, Aronovitz MJ, Deras-Mejia L, Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME, Konstam MA. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol. 1998;274:H1812-H1820.
32. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002;34:951-969.
33. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-577.
34. Bristow M. Of phospholamban, mice, and humans with heart failure. Circulation. 2001;103:787-788. Editorial.
35. Ren J, Hintz KK, Roughead ZK, Duan J, Colligan PB, Ren BH, Lee KJ, Zeng H. Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation. Am J Physiol Heart Circ Physiol. 2003;284:H1800-H1807.
36. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A. 1999;96:11507-11512.
37. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology. 1999;140:800-804.
38. Hegele-Hartung C, Siebel P, Peters O, Kosemund D, Muller G, Hillisch A, Walter A, Kraetzschmar J, Fritzemeier KH. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc Natl Acad Sci U S A. 2004;101:5129-5134.